Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 1,840 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 1,840 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $105.29, for a total transaction of $193,733.60. Following the completion of the sale, the senior vice president directly owned 1,274 shares in the company, valued at approximately $134,139.46. The trade was a 59.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $120.00, for a total value of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $101.95, for a total value of $264,458.30.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM opened at $105.79 on Thursday. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. The stock’s 50 day moving average price is $110.46 and its two-hundred day moving average price is $101.77. The firm has a market capitalization of $6.45 billion, a price-to-earnings ratio of -7.77 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a 12-month low of $50.25 and a 12-month high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The business’s quarterly revenue was up 37.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.12) earnings per share. On average, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on MIRM. TD Cowen lifted their price objective on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. increased their price objective on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, July 2nd. Weiss Ratings cut shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. CLSA set a $146.00 target price on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. Finally, Wolfe Research began coverage on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $143.40.

Institutional Trading of Mirum Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. lifted its position in shares of Mirum Pharmaceuticals by 2.3% during the 2nd quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock worth $539,000 after buying an additional 103 shares during the last quarter. Faithward Advisors LLC raised its stake in Mirum Pharmaceuticals by 0.5% during the first quarter. Faithward Advisors LLC now owns 27,467 shares of the company’s stock worth $2,537,000 after acquiring an additional 126 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Mirum Pharmaceuticals by 6.7% in the fourth quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock worth $253,000 after acquiring an additional 200 shares during the last quarter. Comerica Bank boosted its stake in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its stake in shares of Mirum Pharmaceuticals by 46.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after purchasing an additional 351 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.